伴1q21染色体扩增型多发性骨髓瘤的研究进展

Research Advances in Multiple Myeloma with Chromosome 1q21 Amplification——Review

多发性骨髓瘤(MM)是发生于浆细胞的恶性血液系统疾病。细胞遗传学在MM危险分层中发挥重要作用,1q21扩增是MM常见的异常染色体核型之一。研究表明,1q21扩增与MM患者预后不良相关。目前随着新药的研发、细胞免疫治疗的深入开展及造血干细胞移植技术的提升,MM的缓解深度和生存期明显延长。快速而准确地识别高危患者并根据患者病情给予个体化治疗是提高MM治疗疗效的关键。本文将对1q21扩增与MM发生机制及新型药物治疗伴1q21染色体扩增型MM的疗效最新研究进展作一综述。

Multiple myeloma(MM) is a kind of hematologic malignancy occurring in plasma cells. Cytogenetic technique plays an important role in risk stratification of MM. 1 q21 amplification is one of the common chromosomal abnormalities in MM. Studies have shown that 1 q21 amplification is associated with poor prognosis in MM patients. At present, with the development of new drugs, cellular immunotherapy, and improvement of hematopoietic stem cell transplantation technology, the remission depth and survival time of MM significantly increased. Rapid and accurate identification of high-risk patients and individualized treatment according to the patient’s condition is the key to improve the therapeutic effect of MM. This article reviews the mechanism of 1 q21 amplification in MM and the efficacy of new drugs in the treatment of MM with 1 q21 chromosome amplification.